Yes, I’d like to receive email updates from MSAA! Please provide your email address and zip code so we may alert you about MS-related news, events, and programs happening in your area. * First Name * Last Name * Email * ZIP/Postal Code * Anti-Spam    check box please Your browser does not support Javascript

Yes, I’d like to receive email updates from MSAA! Please provide your email address and zip code so we may alert you about MS-related news, events, and programs happening in your area. * First Name * Last Name * Email * ZIP/Postal Code * Anti-Spam    check box please   – or –   Skip […]

In this Update Main Article Introduction FDA-Approved Medications: Recently Approved New Data on Previously Approved Medications Experimental Medications New Directions in MS Research Closing Notes References Experimental Medications: Monoclonal Antibodies Company: Novartis and Genmab Injected subcutaneously, being studied at 20 mg monthly Being studied in RMS Previous: Plegridy® (peginterferon beta-1a) | Next: Ublituximab The Food and Drug Administration (FDA) is […]

In this Update Main Article Introduction FDA-Approved Medications: Recently Approved New Data on Previously Approved Medications Experimental Medications New Directions in MS Research Closing Notes References FDA-Approved Medications: New Data on Previously Approved Medications: Infused Medications Company: Genentech and Roche Pharma AG Starting dose: 300 mg given via IV infusion, followed two weeks later by a […]

In this Update Main Article Introduction FDA-Approved Medications: Recently Approved New Data on Previously Approved Medications Experimental Medications New Directions in MS Research Closing Notes References FDA-Approved Medications: Medications Recently Approved Company: Biogen Inc. and Alkermes plc Starting dose: 231 mg twice a day, orally, on Days 1-7 Maintenance dose after seven days: 462 mg (administered […]

In this Update Main Article Introduction FDA-Approved Medications: Recently Approved New Data on Previously Approved Medications Experimental Medications New Directions in MS Research Closing Notes References FDA-Approved Medications: Medications Recently Approved Company: Banner Life Sciences Starting dose: 95 mg twice a day, orally, for 7 days Maintenance dose after 7 days: 190 mg (administered as two […]

In this Update Main Article Introduction FDA-Approved Medications: Recently Approved New Data on Previously Approved Medications Experimental Medications New Directions in MS Research Closing Notes References Experimental Medications: Monoclonal Antibodies Company: Biogen Given via IV infusion Being studied in RMS Previous: Ublituximab | Next: Rituxan® (rituximab) Researchers are investigating whether the monoclonal antibody opicinumab reverses neurologic damage and disability when […]